Summit Therapeutics (SMMT) Raises $500 Million Through Public Offering

On June 10, an underwritten nationalist offering of communal banal valued astatine $500 cardinal was initiated by Summit Therapeutics Inc. (NASDAQ:SMMT). The institution stated successful its announcement that 100% of the shares successful this projected transaction are being offered straight by Summit. To negociate and coordinate the equity issuance process, the steadfast has appointed J.P. Morgan, Goldman Sachs & Co., and Citigroup to service arsenic the associated book-running managers.

Tonhom1009/Shutterstock.com

On June 1, pursuing the presumption of Phase 3 HARMONi-6 proceedings information astatine an ASCO plenary session, Cantor Fitzgerald reaffirmed its Overweight standing connected Summit Therapeutics Inc. (NASDAQ:SMMT). As a first-line attraction for squamous non-small compartment lung crab (NSCLC), the China-based probe evaluated the operation of ivonescimab and chemotherapy versus tislelizumab positive chemotherapy.

The ivonescimab operation produced a median progression-free endurance (PFS) of 11 months and a hazard ratio of 0.60, according to antecedently published results astatine ESMO 2025. Overall endurance (OS) information were inactive successful their infancy astatine the time. Cantor pointed retired that worries astir whether PFS enhancements volition yet effect successful an OS payment successful the first-line script are addressed by the interim OS information from HARMONi-6.

The main question astatine manus is whether the Phase 3 HARMONi-3 trial, which is comparing ivonescimab with chemotherapy versus pembrolizumab positive chemotherapy successful first-line NSCLC, tin repetition these favorable results worldwide. The 2nd portion of 2026 is erstwhile results are expected. Although the talker acknowledged that HARMONi-6 showed efficacy successful China, concerns were raised during the ASCO treatment astir the regimen's suitability for patients successful the United States.

Summit Therapeutics Inc. (NASDAQ:SMMT) is simply a clinical-stage biopharma institution that develops and commercializes aesculapian oncology therapies. It is focused connected processing ivonescimab, a bispecific antibody that combines blockade of PD-1 and anti-angiogenesis successful a azygous molecule. It is besides moving Phase III objective trials for the attraction of non-small lung cancer.

While we admit the imaginable of SMMT arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years.

Disclosure: None. Follow Insider Monkey connected Google News.